Logo

CALL TOLL FREE TODAY

1.800.814.4540

Lawyers ⋅ Nurses ⋅ Doctors
Protecting Your Rights for Decades

Medical Devices Defective Drugs Transvaginal Mesh

Abilify

Abilify (aripiprazole), an anti-psychotic medication prescribed to treat schizophrenia, bipolar disorder, depression, and Tourette syndrome, has been linked to compulsive gambling and other behaviors. Over 450 cases have been consolidated before Chief Judge M. Casey Rodgers in the Northern District of Florida in MDL 2734, In re: Abilify (Aripiprazole) Products Liability Litigation (Abilify MDL Case – Northern District of Florida) with Magistrate Judge Gary Jones. Lawyers for the manufacturers, Otsuka Pharmaceutical and Bristol-Myers Squibb, have been ordered, along with settlement counsel, to attend monthly settlement conferences.

Compulsive Gambling

Plaintiffs allege that Abilify was defectively designed or manufactured, that the defendants knew or should have known of the propensity of Abilify to cause compulsive gambling behaviors in users, and that the defendants failed to provide adequate instructions and warnings with this product. Other compulsive behaviors alleged include:

  • Spending and/or Shopping
  • Sexual behavior
  • Pornography
  • Playing video games
  • Compulsive Eating
  • Hoarding
  • Trichotillomania and skin picking
  • Checking, counting, washing, and repeating
  • Theft/Shoplifting
  • Attempted Suicide / Suicidal Thoughts

Drug Label Changes 

In 2002, Abilify was placed on the market and works by increasing dopamine which tends to create uncontrollable urges and impairs decision-making skills. In 2012, after reports of 19 cases of “pathological gambling” in Europe, the manufacturers added a warning on the drug in Europe. In 2015, Canadian regulators concluded that there is “a link between the use of aripiprazole and a possible risk of pathological gambling or hypersexuality” and found an increased risk of pathological (uncontrollable) gambling and hypersexuality with the use of Abilify.” Yet no label changes were made in the USA!

FDA Warning Label FINALLY Changed

In August 2016, warnings regarding compulsive gambling and other compulsive behaviors were added to the Abilify label. The label now warns that “[b]ecause patients may not recognize these behaviors as abnormal, it is important for prescribers to ask patients or their caregivers specifically about the development of new or intense gambling urges, compulsive sexual urges, compulsive shopping, binge or compulsive eating, or other urges while being treated with aripiprazole….Compulsive behaviors may result in harm to the patient and others if not recognized. Consider dose reduction or stopping the medication if a patient develops such urges.”

FDA Links Abilify to Compulsive Gambling, Eating, Shopping and Sex

Plaintiffs list causes of action against the Defendant manufacturers, including:

  • Count I – STRICT LIABILITY
  • Count II – BREACH OF EXPRESS WARRANTY
  • Count III – BREACH OF IMPLIED WARRANTY
  • Count IV – NEGLIGENCE
  • Count V – NEGLIGENCE PER SE
  • Count VI – NEGLIGENT MISREPRESENTATION
  • Count VII – VIOLATION OF CONSUMER PROTECTION LAWS
  • Count VIII – FRAUDULENT CONCEALMENT
  • Count IX – LOSS OF CONSORTIUM
  • Count X – PUNITIVE DAMAGES

CONTACT US FOR A FREE MEDICAL LEGAL EVALUATION

If you or a loved one have taken Abilify and sustained economic loss due to compulsive gambling, contact us for a free medical legal consultation at 800-814-4540 or email carolyn@carolynstclair.com.

Share This Page: